Adam Friedman, MD, Professor and Chair of Dermatology at the George Washington University School of Medicine & Health Sciences in Washington, DC, discusses the U.S. Food and Drug Administration’s approval of dupilumab (Dupixent, Sanofi & Regeneron) for treating chronic spontaneous urticaria (CSU) and its implications for dermatologists.
